Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Myeloproliferative Neoplasms
Barbui, Tefferi
Editore
Springer
Anno
2012
Pagine
240
ISBN
9783642249891
140,00 €
- Comprehensively covers laboratory and clinical advances in polycythemia vera, essential thrombocythemia, and primary myelofibrosis
- Places special emphasis on the practical issues that challenge physicians in their daily practice
- Includes recommendations for the optimization and standardization of treatment
- Written by leading experts in the field
Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are subcategorized into eight clinicopathologic entities. The current book focuses on three of these categories: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. A number of important questions regarding the diagnosis, prognosis, and treatment of these diseases have arisen following the discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative MPNs.
This book comprises evidence-based reviews and expert consensus results. It offers comprehensive coverage of relevant laboratory and clinical advances and places great emphasis on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
vii
Contents
Part I Biology
1 Update on the Biology of Myeloproliferative Neoplasms . . . . 3
Robert Kralovics
2 Do We Need Biological Studies for Patient Management? . . . 11
Moosa Qureshi and Claire Harrison
Part II General Issues in the Management of MPNs
3 Critical Issues About the Diagnosis of MPNs:
Bone Marrow Histopathology . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Jürgen Thiele and Hans Michael Kvasnicka
4 Critical Issues About the Diagnosis of Myeloproliferative
Neoplasms: World Health Organization Classifi cation . . . . . . 37
Mary Frances McMullin
5 Patient’s Information and Examinations Needed Before
Planning Therapy in the Myeloproliferative Neoplasms . . . . . 47
Francisco Cervantes and Juan-Carlos Hernández-Boluda
6 Mechanisms of Thrombogenesis . . . . . . . . . . . . . . . . . . . . . . . . 57
Anna Falanga, Laura Russo, and Marina Marchetti
Part III Specifi c Issues of Treatment in PV and ET
7 Risk Classifi cation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Guido Finazzi
8 Goal of Therapy and Monitoring the Response
in Polycythemia Vera and Essential Thrombocythemia . . . . . 85
Jean-Jacques Kiladjian
9 First-Line Therapy and Special Issues Management
in Polycythemia Vera and Essential Thrombocythemia . . . . . 93
Tiziano Barbui
10 Primary and Secondary Antithrombotic Prophylaxis . . . . . . . 105
Leonardo Di Gennaro and Raffaele Landolfi
viii Contents
11 Polycythemia Vera and Essential Thrombocythemia:
When to Change Therapy – Second-Line Options . . . . . . . . . . . . . . 119
Alessandro M. Vannucchi
12 Blastic Transformation of BCR-ABL-Negative
Myeloproliferative Neoplasms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Madappa N. Kundranda, Raoul Tibes, and Ruben A. Mesa
Part IV Treatment of PMF
13 Current Clinical Needs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Giovanni Barosi
14 Risk Stratifi cation in PMF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Francesco Passamonti
15 Nontransplant Treatment Options for Myelofi brosis:
How to Treat Anemia, Splenomegaly, Constitutional Symptoms,
and Extramedullary Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Ayalew Tefferi
16 Allogeneic Hematopoietic Stem Cell Transplantation
for Myelofi brosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
Nicolaus Kröger
Part V Research Issues and Perspectives
17 A Critical Review of the Role and Limitations of JAK
Inhibitors in Myelofi brosis Therapy . . . . . . . . . . . . . . . . . . . . . . . . . 203
Animesh Pardanani
18 Ongoing Clinical Trials in Myeloproliferative Neoplasms . . . . . . . 215
Fabio P.S. Santos and Srdan Verstovsek
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
